Recent advances in the development of small molecule inhibitors to block ASMase to reduce inflammation in preclinical models of cystic fibrosis are encouraging but unclear for IPF and further studies are necessary to explore the therapeutic potential in lung fibrosis [119,120]. The gene discussed is SMPD1; the disease is cystic fibrosis.